Exelon (rivastigmine) + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cognitive Impairment
Conditions
Cognitive Impairment
Trial Timeline
Feb 1, 2006 → Feb 1, 2008
NCT ID
NCT00669344About Exelon (rivastigmine) + Placebo
Exelon (rivastigmine) + Placebo is a approved stage product being developed by Novartis for Cognitive Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT00669344. Target conditions include Cognitive Impairment.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00669344 | Approved | Completed |
Competing Products
20 competing products in Cognitive Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aricept (donepezil hydrochloride) + placebo | Eisai | Approved | 85 |
| Donepezil | Eisai | Approved | 85 |
| Aricept | Eisai | Phase 2 | 52 |
| Donanemab + Aducanumab | Eli Lilly | Phase 3 | 77 |
| ABT-126 + Placebo | AbbVie | Phase 2 | 52 |
| SDI-118 + Placebo | AbbVie | Phase 1 | 33 |
| ABT-288 Low Dose + Placebo + ABT-288 High Dose | AbbVie | Phase 2 | 52 |
| AZD5213 + AZD5213 + AZD5213 | AstraZeneca | Phase 2 | 52 |
| MK-8931 | Merck | Phase 1 | 33 |
| Nicotine patch + MK-4334 + Placebo patch + Placebo capsule | Merck | Phase 1 | 33 |
| Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2) | Merck | Phase 3 | 77 |
| Rivastigmine | Novartis | Phase 3 | 77 |
| Rivastigmine | Novartis | Approved | 85 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Eviplera | Gilead Sciences | Approved | 84 |
| atorvastatin | Pfizer | Pre-clinical | 22 |
| bosutinib | Pfizer | Phase 1 | 32 |
| Aducanumab + Placebo | Biogen | Phase 2 | 49 |
| BIIB080 + BIIB080-matching placebo | Biogen | Phase 2 | 49 |
| BIIB104 | Biogen | Phase 2 | 49 |